Guardant blood test shows promise in pre­dict­ing im­munother­a­py re­sponse; As­traZeneca's di­a­betes drug wins EU la­bel ex­pan­sion

→ The field of liq­uid biop­sy is bur­geon­ing, and each play­er (there are plen­ty) is dogged­ly pur­su­ing con­sis­ten­cy and ac­cu­ra­cy — false pos­i­tives in­duce un­nec­es­sary anx­i­ety, and are cost­ly. Late on Sun­day, Guardant Health said its as­say, Guardant360, showed in a study it can ac­cu­rate­ly de­tect mi­crosatel­lite in­sta­bil­i­ty (MSI), a key bio­mark­er used to pre­dict re­sponse to im­munother­a­py re­gard­less of tu­mor type. MSI is a change that oc­curs in the DNA of cer­tain cells (such as tu­mor cells) in which the num­ber of re­peats of mi­crosatel­lites (short, re­peat­ed se­quences of DNA) is dif­fer­ent than the num­ber of re­peats that was in the DNA when it was in­her­it­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.